Hyaluronic acid preparations in the treatment of osteoarthritis. Synvisk®(Hylan G-F 20): Efficacy and safety
https://doi.org/10.14412/1996-7012-2013-2444
Abstract
The paper presents data on osteoarthrosis treatment using hyaluronic acid (HA) preparations, on the functions of hyaluronan (HN) in synovial fluid (SF), synovial tissue, and articular cartilage, and on differences in the symptom-modifying effect of HN with varying molecular weight. HN with average molecular weight demonstrates its benefits. The analgesic effect of HA preparations is shown to be determined by not only the improvement of SF elastoviscous properties and by the protection of pain receptors in joint tissues, but by their anti-rheumatic properties.
About the Author
Natalia Vladimirovna Chichasova
Department of Rheumatology, Faculty for Postgraduate and Advanced Training of Physicians, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. <div><p>Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumаtol. 2002;14(5):573–7. DOI: http://dx.doi.org/10.1097%2F00002281-200209000-00017.</p><p>Kadam UT, Jordan K, Craft PR. Clinical comorbidity in patients with оsteoarthritis: a case-control study of general practice consulters in England and Walls. Ann Rheum Dis. 2004;63(4):408–14.</p><p>Breivik H, Collett B, Ventafridda V et al. Survey of chronic pain in Europe:</p><p>prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10(4):287–333. Epub 2005 Aug 10. DOI: http://dx.doi.org/10.1016%2Fj.ejpain.2005.06.009.</p><p>Pincus T, Sokka T. Abstract presented during the American College of Rheumatology, 2005. Scientific Sessions. San Diego, California.</p><p>Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients.The medicine may be worse than the disease. BMJ. 1995;310:817–8.</p><p>Ostensen M. Cartilage changes in arthritis do non-steroidal antiphlogistics have positive or negative effects? Tidsskr Nor Laegeforen.1991;111:838–40.</p><p>Haskall VC, Laurent TC. Hyaluronan structure and physical properties. 1997. Available at: //www/glycoforum.gr.jp.scince/hyaluronan/HAO1/HAO1E.html</p><p>Gahl LB, Dahl IMS, Engstrom A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis, 1985;44(12):817–22.</p><p>Balazs EA, Denlinger JL. Viscosupplemetation: a new concept in the treatment of osteoarthritis. J Rheum. 1993;39:3–9.</p><p>Goldenberg VM, Bucwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. 2005;13(3):216–24.</p><p>Uebelhart D, Williams JM. Effect of hyaluronic acid on cartilage degradation. Curr Opin Rheum. 1999;11(5):427–35. DOI: http://dx.doi.org/10.1097%2F00002281-199909000-00018.</p><p>Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effect molecular weights dependent? Semin Arthr Rheum. 2002;32(10):10–37. DOI: http://dx.doi.org/10.1053%2Fsarh.2002.33720.</p><p>Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin Exp Rheum. 2001;19(3):242–6.</p><p>Takahashi K, Goomer RS, Harwood F et al. The effect of hyaluronan on matrix metalloprotease-3 (MMP-3), interleukin-1 beta(IL-1beta), and tissue inhibitor of metalloprotease-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage. 1999;7(2):182–90.</p><p>Julovi SM, Yasuda T, Shimizu M et al. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50(2):516–25.</p><p>Tetlow LC, Adlam DJ, Wooley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: association with degenerative changes. Arthritis Rheum. 2001;44(3):585–94. DOI: http://dx.doi.org/10.1002%2F1529-0131%28200103%2944%3A3%3C585%3A%3AAID-ANR107%3E3.0.CO%3B2-C.</p><p>Takahashi K, Hashimoto S, Kubo T et al. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol. 2000;27(7):1713–20.</p><p>Hulmes DJ, Marsden ME, Strachan RK et al. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthritis Cartilage. 2004;12(3):232–8. DOI: http://dx.doi.org/10.1016%2Fj.joca.2003.11.007.</p><p>Corrado EM, Peluso GF, Gigliotti S et al. The effects of intraarticular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. Eur J Rheum Infl. 1995;15:47–56.</p><p>Lisignoli G, Grassi F, Zani N et al. Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan. Arthritis Rheum. 2001;44(8):1800–7. DOI: http://dx.doi.org/10.1002%2F1529-0131%28200108%2944%3A8%3C1800%3A%3AAID-ART317%3E3.0.CO%3B2-1.</p><p>Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodiumhyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage. 1993;1(2):97–103. DOI: http://dx.doi.org/10.1016%2FS1063-4584%2805%2980024-X .</p><p>Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol. 1998;25(11):2203–12.</p><p>Huskisson EC, Donnely S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford). 1999;38(7):602–7. DOI: http://dx.doi.org/10.1093%2Frheumatology%2F38.7.602.</p><p>Puhl W, Bernau A, Greiling H et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage. 1993;1(4):233–41. DOI: http://dx.doi.org/10.1016%2FS1063- 4584%2805%2980329-2.</p><p>Brandt KD, Block JA, Mishalski JP et al. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHO-VISC Study Group. Clin Orthop Relat Res. 2001;(385):130–43.</p><p>Lohmander LS, Dalen N, Englund G et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicenter trial. Ann Rheum Dis. 1996;55(7):424–31. DOI: http://dx.doi.org/10.1136%2Fard.55.7.424.</p><p>Barrett JP, Siviero P. Retrospective study of outcomes in Hyalgan-treated patients with osteoarthritis of the knee. Clin Drug Investing. 2002;22(2):87–97. DOI: 10.2165/00044011-200222020-00003.</p><p>Lussier A, Cividino AA, McFarlane CA et al. Viscosupplemetation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23(9):1579–85.</p><p>Kazimir J, Simkanin P, Bancziova E et al. Hyalgan in the treatment of osteoarthritis. A postmarketing study, January – June 1998. Rehabilit. 1998;31.</p><p>Shimizu C, Kubo T, Hirasawa Y et al. Histimorphometric and biochemical effect of various hyaluronans on early osteoarthritis. J Rheumatol. 1998;25(9):1813–9.</p><p>Kukuchi T, Yamada H, Shimmer M. Effect of high molecular weight hyaluronan on cartilage degradation in a rabbit model of osteoarthritis. Osteoarthritis Cartilage. 1996;4(2):99–110.</p><p>Vitanzo PC, Sennett BJ. Hyaluronans: is clinical effectiveness dependent on molecular weight. Am J Orthop (Belle Mead NJ). 2006;35(9):421–8.</p><p>Undqvist U, Tolmachev V, Kalremo K et al. Elimination of stablised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603–13.</p><p>Lindenhayan K, Hellman HH, Nederhausen T et al. Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. Eur J Clin Chem Clin Biochem. 1997;35(5):355–63. DOI: http://dx.doi.org/10.1515%2Fcclm.1997.35.5.355.</p><p>Brown T, Laurent U. Turnover of hyaluronan in synovial joints: elimination of labeled hyaluronan from the knee joint of rabbit. Exp Physiol. 1991;76(1):125–34.</p><p>Cubukcu D, Ardic F, Karabulut N, Topuz O. Hylan GF 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clin Rheumatol. 2005;24(4):336–41. Epub 2004 Dec 14.</p><p>Seale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritis knees with hyalgan: A treatment schedule study. Curr Ther Res. 1994;55:220–32.</p><p>Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial on efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410–23. DOI: http://dx.doi.org/10.1016%2FS0149-2918%2898%2980052-0.</p><p>Chevalier X, Jerosch J, Goupille P et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicenter, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113–9. DOI: 10.1136/ard.2008.094623.</p><p>Conrozier T, Jerosch J, Beks P et al. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation wih hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009 Mar;129(3):417–23. DOI: 10.1007/s00402-008-0601-2. Epub 2008 Mar 26.</p><p>Wobig M, Bach G, Beks P et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999;21:1549–62. DOI: http://dx.doi.org/10.1016%2FS0149-2918%2800%2980010-7.</p><p>Raman R, Duta A, Day N et al. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee – a prospective randomized clinical trial. Knee. 2008;15:318–24. DOI: 10.1016/j.knee.2008.02.012. Epub 2008 Apr 21.</p><p>Rarlsson J, Sjogren LS, Lohmaner LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology (Oxford). 2002;41(11):1240–8.</p><p>Bellamy N, Campbell J, Robinson V et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;19(2):CD005321.</p><p>Raynauld JP, Torrance GW, Band PA et al.; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into to treatment paradigm for patients with knee osteoarthritis (Part1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10(7):506–17.</p><p>Caborn D, Rush JL, Lanzer W et al. A randomized single blind comparison of the efficacy and tolerability of Hylan GF-20 and triamcinolone hexaacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333–43.</p><p>Yustin D, Kryshtalskyj B, Galea A. Use of Hylan G-F 20 for viscosupplementation of the temporomandibular joint for the management of osteoarthritis: a case report. J Orofac Pain. 1995;9(4):375–9.</p><p>Figen Ayhan F, Ustin N. The evaluation of efficacy and tolerability of Hylan G-F 20 in bilateral; thumb base osteoarthritis: 6 months follow-up. Clin Rheumatol. 2009;28(5):535–41. DOI: 10.1007/s10067-008-1080-0. Epub 2009 Jan 10.</p><p>Mandl LA, Hotchkiss RM, Adler RS et al. Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial. Curr Med Res Opin. 2009;25(9):2103–8. DOI: 10.1185/03007990903084016.</p><p>Wang Y, Hall S, Hanna F. Effect of hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMS Muskuloskelet Disord. 2011;12:195–203. DOI: 10.1186/1471-2474-12-195.</p><p>Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol. 1998;16(4):441–9.</p><p>Listrat V, Ayral X, Patarnello F et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage. 1997;5(3):153–60. DOI: http://dx.doi.org/10.1016%2FS1063-4584%2897%2980010-6.</p><p>Jubb RW, Piva S, Beinat L et al. A one-year, randomised, placebo (saline) controlled trial of 530-700 kDda sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57:467–74.</p><p>Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis. 2004;63(3):264–8. DOI: http://dx.doi.org/10.1136%2Fard%2F2003.007666.</p><p>Cicuttini FM, Jones G, Forbes A et al. Rate of cartilage loss at two years predicts sub sequent total knee arthroplasty: a prospective study. Ann Rheum Dis. 2004;63(9):1124–7. Epub 2004 Apr 28.</p><p>Migliori A, Bizzi E, Massafra U et al. The impact of treatment with Hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr Med Res Opinion. 2012;28(5):755–60. DOI: 10.1185/03007995.2011.645563. Epub 2012 Apr 18.</p><p>Pullman-Mooar S, Mooar P, Sieck M et al. Are there distinctive inflammatory flares of synovitis after hylan GF intraarticular injections? J Rheumatol. 2002 Dec;29(12):2611–4.</p><p>Puttic MP, Wade JP, Chalmers A et al. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995;22(7):1311–4.</p><p>Bernardeu C, Bucki B, Liote F. Acute arthritis after intraarticular hyaluronate injection: onset of effusion without crystal. Ann Rheum Dis. 2001;60(5):518–20.</p><p>Bucher W, Otto T, Hamburger MI. Differentiation of hyaluronate products by qualitative difference in their immunogenicity in rabbits: a possible mechanism for productspecific severe adverse reaction? Arthritis Rheum. 2002;46(9):2543–4. DOI: http://dx.doi.org/10.1002%2Fart.10450.</p><p>Kahan A, Leu P-L, Salin A. Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine. 2003;70(4):276–81. DOI: http://dx.doi.org/10.1016%2FS1297-319X%2803%2900043-5.</p><p>Palm T, van der Heijde D, Altman RD. Outcome variables for osteoarthritis clinical trials. J Rheumatol. 2003;30(7):1648–54.</p></div><br />
Review
For citations:
Chichasova NV. Hyaluronic acid preparations in the treatment of osteoarthritis. Synvisk®(Hylan G-F 20): Efficacy and safety. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2013;7(4):85-91. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2444
Views:
3721
Email this article 